'Sold to the Universities for $1' — Banting, Best & Collip's Insulin Patent US1469994 Was Jointly Assigned to **Both** the University of Toronto **and** the University of Alberta

About excavation memos: Memos record candidates at the stage where the primary-source URL has been confirmed but the body has not yet been fully read. Only verified facts are stated; speculation is marked as such.

Why dig

July 14 is celebrated worldwide as one prelude to "World Diabetes Day," tied to Frederick Banting's birthday (1891). Insulin was discovered in 1921 in the physiology laboratory at the University of Toronto, and in 1923 Banting and John Macleod received the Nobel Prize in Physiology or Medicine. (Banting famously shared his prize money with Best, and Macleod shared his with Collip.)

The popular narrative — repeated in textbooks, the Nobel Prize museum, and Canadian history curricula — is that the discoverers "sold the patent to the university for $1." This is treated as a symbol of the ideal that "medicine should belong to humanity."

Open the patent itself on Google Patents. US1469994 (granted 1923). Title: "Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it." Filed January 12, 1923; granted October 9, 1923.

The DB (~/ai-archaeology/db/candidates.tsv) row PH-002 records "Banting/Best/Collip sold to UoT for $1." But the Original Assignee field on Google Patents shows University of Toronto and University of Alberta as joint assignees. Because Collip held an Alberta affiliation, his share was assigned to Alberta. The simplification "sold to the University of Toronto alone" had crept into the DB.

Patent header

• Patent number: US1469994
• Title: Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it
• U.S. filing date: January 12, 1923
• U.S. grant date: October 9, 1923
• Inventors: Frederick G. Banting / Charles H. Best / James B. Collip — three co-inventors (the DB record of "Banting/Best, two inventors" is wrong)
• Original Assignee: University of Toronto and University of Alberta (joint; the DB record of "UoT alone" is wrong)
• Current Assignee: University of Alberta and University of Toronto
• U.S. expiration: October 9, 1940 (20 years from grant)
• Primary source: Google Patents (URL confirmed; title, full Claim 1, three inventors, filing date, grant date, and assignees all retrieved)

The core (information retrieved from Google Patents)

Claim 1 reads:

A substance prepared from fresh pancreatic or related glands containing in concentrated form the extractive from the ductless portion of the gland suitably free from injurious substances for repeated administration and having the physiological characteristics of causing a reduction of blood sugar useful for the treatment of diabetes mellitus.

Four elements: (1) prepared from fresh pancreatic or related glands (including the related glands in fishes); (2) contains in concentrated form the extractive from the ductless portion (= islets of Langerhans); (3) suitably free from injurious substances for repeated administration; (4) reduces blood sugar for diabetes treatment.

The "ductless portion" qualifier is critical. The pancreas is a mixed organ — exocrine glands with ducts (secreting digestive enzymes) and endocrine glands without ducts (secreting hormones, i.e., islets of Langerhans). Since the late 19th century the hypothesis that islets controlled glucose metabolism existed, but the digestive enzymes from the exocrine portion broke down insulin during extraction, making isolation extraordinarily difficult.

Banting's original idea, conceived in October 1920, was: "If we ligate the pancreatic duct so the exocrine portion atrophies, we can then extract the islet portion without enzymatic degradation." In summer 1921, while Professor Macleod was away, Banting and Best began experiments with dogs at the University of Toronto's physiology laboratory. They confirmed that "isletin" (later renamed insulin) extracted from duct-ligated pancreas reduced blood glucose in diabetic dogs.

But Banting & Best's early extracts were impure (protein contaminants, toxins), causing severe side effects in humans. Collip was called to Toronto in December 1921 as a biochemist and designed an alcohol-precipitation purification process that produced human-injectable refined insulin. On January 11, 1922, the world's first human dose (Banting & Best's crude extract) was given to a 14-year-old diabetic boy, Leonard Thompson, but was discontinued due to side effects. Twelve days later, on January 23, Collip's purified insulin produced dramatic clinical effects.

When the patent was filed (January 12, 1923), each of the three inventors transferred their respective shares to their respective universities for $1. Banting and Best assigned to the University of Toronto, Collip to the University of Alberta — making the Original Assignee field show both universities as joint assignees. Exclusive licenses were then granted to Eli Lilly (US) and Connaught Laboratories (Canada), and commercial production began in 1923.

Modern connection (includes speculation)

How to read this table.

Rows 1-2: Same. "Animal-pancreas extraction" and "islet beta-cell targeting" remained the mainstream until recombinant DNA technology arrived in the 1980s.

Row 3: Similar. Alcohol precipitation is still a basic tool in modern pharmaceutical purification, but it's now combined with chromatography and ultrafiltration.

Row 4 (the $1 transfer mapped to the modern pricing problem): Stretched. US1469994 expired in 1940. The modern pricing problem is driven by (a) recombinant human insulin (1982-), (b) analog insulins (1996-, e.g., Lispro), (c) long-acting and rapid-acting formulations — all new patent families plus Pharmacy Benefit Manager (PBM) distribution structure. There is no causal chain from the 1923 patent. The narrative "the $1-transfer ideal was betrayed" is emotionally clear but historically weak as patent history.

Rows 5-6: Similar. The "university-invention commercialization scheme" (exclusive licensing, royalties, manufacturer selection) Toronto established in 1922-1923 is not the direct predecessor of the post-1980 Bayh-Dole-era US university TLO model, but the problem set overlaps: how do you transfer publicly funded research results to the private sector? It can be read as a rare implementation of that question in 1923.

Row 7: Metaphor. 1923 insulin was an "animal-pancreas extract." Post-1982 recombinant human insulin is a "human-insulin molecule expressed in E. coli or yeast." Both are called "insulin," but the molecular composition (cow/pig insulin differs from human by 2-3 amino acids), manufacturing method, purity, and side-effect profile are all different.

Why is this worth digging? (speculation)

Reason 1: The fact "three inventors + two-university joint assignment" tends to be deleted from textbooks.

Textbooks and popular books circulate the simplified narrative "Banting and Best discovered insulin and sold it to the University of Toronto for $1." In reality Collip designed the purification process, and each of the three transferred their shares to their respective home universities for $1. The fact that the University of Alberta is registered as an Original Assignee is an institutional record acknowledging Collip's contribution — but it gets buried under the Nobel Prize allocation drama (Macleod sharing with Collip in response to Banting's criticism that "Macleod wasn't directly involved in the experiments").

Reason 2: The 1923 Claim 1 style is a useful reference for modern patents.

Claim 1 combines "substance properties (a substance with X effect)" and "method of preparation (prepared from Y)" — an early example of what we now call a "product-by-process claim." The phrase "suitably free from injurious substances" embeds a safety description, which can be read as an ideological precursor of modern pharmaceutical regulatory purity requirements (FDA, EMA).

Reason 3: A discussion piece for the modern insulin pricing debate.

US1469994 expired in the US in 1940, so generic insulin (including biosimilars) has theoretically been manufacturable since then. The reason US insulin prices remain high is a composite of new patents on recombinant human insulin and analog insulins, the PBM distribution structure, and the Eli Lilly / Sanofi / Novo Nordisk three-firm oligopoly. Connecting "the $1-transfer ideal" directly to "modern high prices" is rhetoric; sober analysis requires separating patent history, regulatory history, and health economics. This memo positions itself as the starting point of that analysis by primary-sourcing the Claim 1 and the assignment record of US1469994.

Pitfalls

Pitfall 1: "Banting & Best discovered, Macleod & Collip were sidekicks" is an oversimplification.

The Nobel Prize allocation drama (Banting criticizing Macleod's involvement, Macleod proposing to share with Collip, the actual sharing being Banting → Best, Macleod → Collip) generated a popular narrative downgrading Macleod and Collip. In reality the contribution was four-way: (1) Banting & Best progressed experiments during Macleod's absence, (2) Macleod improved experimental design after returning, (3) Collip's purification process enabled human dosing, (4) Macleod negotiated commercialization with Eli Lilly. The Nobel Committee selected "lab principal investigators" — Banting and Macleod.

Pitfall 2: "$1 transfer = waiving the patent" is incorrect.

The three transferred their shares to the universities, not "abandoned" the patent. Toronto (and Alberta) held the patent rights, granted exclusive licenses to Eli Lilly and others, and collected royalties. From 1923 to 1941 (until expiration), the universities collected royalties from pharmaceutical companies worldwide and applied the income to insulin research and internal grants. "Medicine belongs to everyone" was a transfer-time slogan; the actual structure was "the university holds the patent and controls commercialization."

Pitfall 3: "Insulin patent expired, so generics should follow" is half wrong.

US1469994 expired in 1940. But "animal-derived insulin" generics had no demand after the 1980s — recombinant human insulin (Genentech 1982 / Eli Lilly Humulin commercial 1982) replaced it. Recombinant human insulin and derived analogs (Lispro, Aspart, Glargine, etc.) are protected by new patent families, and even after their expiration, hurdles like manufacturing know-how, regulatory approval, and distribution networks slow biosimilar entry. This is why price competition is rare in the US market.

Pitfall 4: Don't confuse "Nobel Prize narrative = patent history."

The Nobel Prize drama (Banting/Macleod/Best/Collip allocation debate) and the patent history (who invented what, who assigned to whom, who licensed) are different historical axes. The Nobel narrative tells a hero story of Toronto-centric medical research; the patent history institutionally records Collip's Alberta contribution. Both must be read separately.

Strictly speaking

Confirmed facts From Google Patents: US1469994 / U.S. filing 1923-01-12 / U.S. grant 1923-10-09 / Inventors: Frederick G. Banting, Charles H. Best, James B. Collip (three co-inventors) / Original Assignee: University of Toronto and University of Alberta (joint) / Current Assignee: University of Alberta and University of Toronto / Claim 1 full text retrieved (see above) / Title: "Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it" / Expiration 1940-10-09.

Author's interpretation The mappings between "medicine belongs to everyone" and "$1 transfer," between "Nobel Prize allocation drama" and "Collip's institutional record," and between "modern pricing" and "the 1923 patent's weak causation" are author interpretations. The exact transfer dates and contract texts cannot be confirmed through Google Patents alone — the University of Toronto's official archive (Insulin Story, https://insulin.library.utoronto.ca/) holds scanned contract images, but they were not accessed in this pass.

Metaphor / analogy Row 4 (the $1 transfer mapped to the modern pricing problem) is closer to "stretched." Modern pricing is set by post-expiration recombinant insulin patents and PBM distribution; the causal chain to the 1923 patent is weak. Row 7 (1923 animal insulin vs 1982 recombinant human insulin) is metaphor. Both are called "insulin," but molecule, manufacturing method, and purity profile are different.

Unconfirmed Full text of Claim 2 onwards / verbatim confirmation of the full Description / the original three-inventor patent transfer contracts of January 1923 (available at the University of Toronto archive but not accessed) / original exclusive license contracts with Eli Lilly and Connaught Laboratories / annual records of Toronto's insulin patent royalty income / primary medical record of the January 11, 1922 Leonard Thompson dosing / primary lab notebooks from the summer 1921 Banting & Best dog experiments / internal Nobel selection committee documents from the 1923 prize / comprehensive list of post-1980 recombinant insulin and analog insulin patent families / details of the PBM (Pharmacy Benefit Manager) distribution structure.

Where this comparison breaks down US1469994 is the 1923 animal-derived insulin manufacturing patent; the modern pricing problem is driven by post-1980 recombinant insulin and analog insulin patent families plus PBM distribution structure. Connecting them directly is rhetoric; the patent-history causal chain is weak. Writing "the $1-transfer ideal was betrayed" requires analyzing (1) which patents currently maintain insulin prices, (2) their expiration schedule, (3) the role of PBMs, (4) the FDA biosimilar approval system. This memo is limited to Google Patents-level confirmation; full Description, Toronto archive contracts, post-expiration insulin patent families, and modern health-economics analysis are not retrieved.

References:

• Source patent: US1469994 on Google Patents
• Related excavation note (Pharma Patents): Cetus PCR foundational patent US4683195A (1985)
• Related excavation memo #1 (Pharma Patents): Akira Endo statin foundational patent US4049495A (1974 priority)
• University of Toronto, "The Discovery and Early Development of Insulin" (primary source archive, not accessed in this pass): https://insulin.library.utoronto.ca/